title: Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer.
abstract: Between April 1997 and March 1998 we evaluated the immune response and outcome in 11 chemosensitive patients who were treated with the anti-idiotype antibody vaccine TriAb after recovery from intensive therapy and autologous stem cell transplant (ASCT). Triab was commenced after recovery from the acute effects of ASCT; a minimum interval of 1 month was required from completion of consolidation radiotherapy, if given. Nine patients (82%) manifest anti-anti-idiotype antibody (Ab3) responses post ASCT. The maximal Ab3 response was seen after a median of 10 doses (range 5-20), which corresponded to a median of 14 months (range 5-19) post ASCT. Evidence of a T cell proliferative response was seen in eight patients; the response was modest in most of these. At a median follow-up of 24 months (range 22-33) after ASCT, four patients are alive without evidence of disease progression. All four of these patients were in the subgroup with more vigorous immune responses. Subsequent efforts have been directed toward the achievement of higher levels of immune responses more rapidly post ASCT. Bone Marrow Transplantation (2000) 26, 729-735.
authors.affiliation: University of Kentucky, Blood and Marrow Transplant Program, Lexington,KY 40536-0093, USA.
authors.forename: D E
authors.initials: DE
authors.lastname: Reece
authors.forename: K A
authors.initials: KA
authors.lastname: Foon
authors.forename: M
authors.initials: M
authors.lastname: Bhattacharya-Chatterjee
authors.forename: G A
authors.initials: GA
authors.lastname: Hale
authors.forename: D S
authors.initials: DS
authors.lastname: Howard
authors.forename: R K
authors.initials: RK
authors.lastname: Munn
authors.forename: R
authors.initials: R
authors.lastname: Nath
authors.forename: B A
authors.initials: BA
authors.lastname: Plummer
authors.forename: A
authors.initials: A
authors.lastname: Teitelbaum
authors.forename: G L
authors.initials: GL
authors.lastname: Phillips
mesh_terms: D000328:Adult; D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use* / Q000633:toxicity; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000276:immunology / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy; D008207:Lymphatic Metastasis / Q000276:immunology; D008213:Lymphocyte Activation; D008875:Middle Aged; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines